Mucinous pancreatic cystic lesions (PCLs) significantly increase cancer risk but can be difficult to identify. A study indicates that endoscopic ultrasound-guided intracystic glucose measurement effectively distinguishes mucinous from non-mucinous PCLs, boosting sensitivity to 88-95% and specificity to 76-91%, surpassing traditional carcinoembryonic antigen (CEA) tests. By coupling glucose analysis with DNA-based biomarkers, clinicians can enhance risk stratification for surgical decisions, improving patient management while reducing unnecessary surgeries for benign conditions. Future studies should focus on standardizing practices.
Review by Bruni A, Tuccillo L (…) Barbara G et 8 al. in J Clin Med